{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE330nnn/GSE330648/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330648"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"A quadrivalent in vivo CAR-macrophage repress solid tumors and overcome tumor heterogeneity through antigen spreading","description":"We designed a quadrivalent in vivo CAR-engineered macrophage based on the LNP-mRNA system, delivering FAP CAR-ΔTGFβRII and GPC3 CAR-Super IL2 (LNP-GF CAR) via LNP for the treatment of primary hepatocellular carcinoma. LNP-GF CAR demonstrated significant anti-tumor efficacy in a primary hepatocellular carcinoma mouse model. To further dissect the anti-tumor mechanism of LNP-GF CAR, we performed single-cell transcriptomic sequencing on tumor regions of the liver from treated model mice. Based on the single-cell transcriptomic data, we found that exogenous CAR mRNA was highly enriched in tissue-resident macrophages within the liver tumor regions. CAR-expressing macrophages showed significant upregulation of genes related to antigen cross-presentation and promotion of T cell activation and proliferation. Consistently, the numbers of proliferative and activated CD8 T cells were significantly increased. These findings provide further evidence that in situ CAR macrophages can activate CD8 T cells through antigen cross-presentation, and deepen our understanding of the anti-tumor mechanism of LNP-GF CAR.","dates":{"publication":"2026/05/16"},"accession":"GSE330648","cross_references":{"GSM":["GSM9729834","GSM9729833","GSM9729836","GSM9729835"],"GPL":["24247"],"GSE":["330648"],"taxon":["Mus musculus"]}}